Question

A 2 page assignment of Defining the Industry - Biogen

Answer 1

Answer.

Biogen, Inc. (already known as Biogen Idec) is an American multinational biotechnology company situated in Cambridge, Massachusetts, having some expertise in the disclosure, advancement, and conveyance of therapies for the treatment of neurodegenerative, hematologic, and autoimmune ailments to patients around the world.

Biogen was established in 1978 in Geneva by a few noticeable biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who filled in as CEO amid the start-up stage), Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich (who contributed the main item interferon alpha). Gilbert and Sharp were hence regarded with Nobel Prizes: Gilbert was perceived in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp got the Nobel Prize in Physiology or Medicine in 1993 for his disclosure of split genes.

In 2003, Biogen converged with San Diego, California-based IDEC Pharmaceuticals (framed in 1986 by biotech pioneers Ivor Royston, Howard Birndorf and Robert E. Sobol) and received the name Biogen Idec. After the merger, Biogen Idec turned into the third biggest Biotechnology company in the world.Following movements in inquire about center zones, the company has since abbreviated its name, returning to just Biogen. Biogen stock is a part of a few stock lists, for example, the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is recorded on the NASDAQ stock trade under the ticker image, BIIB.